Frankell, Alexander M. http://orcid.org/0000-0002-0341-7878
Dietzen, Michelle http://orcid.org/0000-0002-6853-7563
Al Bakir, Maise http://orcid.org/0000-0002-0846-8332
Lim, Emilia L.
Karasaki, Takahiro http://orcid.org/0000-0001-6863-2360
Ward, Sophia http://orcid.org/0000-0002-6777-5279
Veeriah, Selvaraju
Colliver, Emma http://orcid.org/0000-0002-1497-0740
Huebner, Ariana http://orcid.org/0000-0001-8009-4999
Bunkum, Abigail http://orcid.org/0000-0002-7753-9421
Hill, Mark S. http://orcid.org/0000-0003-0718-8934
Grigoriadis, Kristiana http://orcid.org/0000-0002-8435-0176
Moore, David A. http://orcid.org/0000-0002-6296-1312
Black, James R. M.
Liu, Wing Kin
Thol, Kerstin
Pich, Oriol http://orcid.org/0000-0002-1956-1882
Watkins, Thomas B. K.
Naceur-Lombardelli, Cristina
Cook, Daniel E. http://orcid.org/0000-0003-3347-562X
Salgado, Roberto
Wilson, Gareth A.
Bailey, Chris
Angelova, Mihaela http://orcid.org/0000-0002-0495-9695
Bentham, Robert
Martínez-Ruiz, Carlos http://orcid.org/0000-0002-4817-0565
Abbosh, Christopher http://orcid.org/0000-0002-8983-1382
Nicholson, Andrew G.
Le Quesne, John http://orcid.org/0000-0003-3552-7446
Biswas, Dhruva http://orcid.org/0000-0001-9141-5188
Rosenthal, Rachel
Puttick, Clare
Hessey, Sonya http://orcid.org/0000-0001-9856-424X
Lee, Claudia http://orcid.org/0000-0003-1715-2265
Prymas, Paulina
Toncheva, Antonia
Smith, Jon
Xing, Wei
Nicod, Jerome http://orcid.org/0000-0003-2459-3480
Price, Gillian
Kerr, Keith M.
Naidu, Babu
Middleton, Gary http://orcid.org/0000-0001-5695-3474
Blyth, Kevin G.
Fennell, Dean A.
Forster, Martin D.
Lee, Siow Ming
Falzon, Mary
Hewish, Madeleine
Shackcloth, Michael J.
Lim, Eric
Benafif, Sarah
Russell, Peter
Boleti, Ekaterini
Krebs, Matthew G.
Lester, Jason F.
Papadatos-Pastos, Dionysis
Ahmad, Tanya
Thakrar, Ricky M.
Lawrence, David
Navani, Neal
Janes, Sam M.
Dive, Caroline
Blackhall, Fiona H.
Summers, Yvonne
Cave, Judith
Marafioti, Teresa
Herrero, Javier http://orcid.org/0000-0001-7313-717X
Quezada, Sergio A. http://orcid.org/0000-0002-9763-1700
Peggs, Karl S.
Schwarz, Roland F.
Van Loo, Peter http://orcid.org/0000-0003-0292-1949
Miedema, Daniël M.
Birkbak, Nicolai J. http://orcid.org/0000-0003-1613-9587
Hiley, Crispin T.
Hackshaw, Allan http://orcid.org/0000-0002-5570-5070
Zaccaria, Simone http://orcid.org/0000-0002-5265-7392
Le Quesne, John
Van Loo, Peter
Bajaj, Amrita
Nakas, Apostolos
Sodha-Ramdeen, Azmina
Ang, Keng
Tufail, Mohamad
Chowdhry, Mohammed Fiyaz
Scotland, Molly
Boyles, Rebecca
Rathinam, Sridhar
Wilson, Claire
Marrone, Domenic
Dulloo, Sean
Matharu, Gurdeep
Shaw, Jacqui A.
Riley, Joan
Primrose, Lindsay
Cheyne, Heather
Khalil, Mohammed
Richardson, Shirley
Cruickshank, Tracey
Gilbert, Kayleigh
Patel, Akshay J.
Osman, Aya
Lacson, Christer
Langman, Gerald
Shackleford, Helen
Djearaman, Madava
Kadiri, Salma
Leek, Angela
Hodgkinson, Jack Davies
Totten, Nicola
Montero, Angeles
Smith, Elaine
Fontaine, Eustace
Granato, Felice
Doran, Helen
Novasio, Juliette
Rammohan, Kendadai
Joseph, Leena
Bishop, Paul
Shah, Rajesh
Moss, Stuart
Joshi, Vijay
Crosbie, Philip
Gomes, Fabio
Brown, Kate
Carter, Mathew
Chaturvedi, Anshuman
Priest, Lynsey
Oliveira, Pedro
Lindsay, Colin R.
Clipson, Alexandra
Tugwood, Jonathan
Kerr, Alastair
Rothwell, Dominic G.
Kilgour, Elaine
Aerts, Hugo J. W. L.
Kaufmann, Tom L.
Szallasi, Zoltan
Kisistok, Judit
Sokac, Mateo
Diossy, Miklos
Demeulemeester, Jonas
Stewart, Aengus
Magness, Alastair
Rowan, Andrew
Karamani, Angeliki
Chain, Benny
Campbell, Brittany B.
Castignani, Carla
Weeden, Clare E.
Richard, Corentin
Pearce, David R.
Karagianni, Despoina
Levi, Dina
Hoxha, Elena
Larose Cadieux, Elizabeth
Nye, Emma
Grönroos, Eva
Gálvez-Cancino, Felip
Athanasopoulou, Foteini
Gimeno-Valiente, Francisco
Kassiotis, George
Stavrou, Georgia
Mastrokalos, Gerasimos
Zhai, Haoran
Lowe, Helen L.
Matos, Ignacio
Goldman, Jacki
Reading, James L.
Rane, Jayant K.
Lam, Jie Min
Hartley, John A.
Enfield, Katey S. S.
Selvaraju, Kayalvizhi
Litchfield, Kevin
Ng, Kevin W.
Chen, Kezhong
Dijkstra, Krijn
Thakkar, Krupa
Ensell, Leah
Shah, Mansi
Vasquez, Marcos
Litovchenko, Maria
Werner Sunderland, Mariana
Leung, Michelle
Escudero, Mickael
Tanić, Miljana
Sivakumar, Monica
Kanu, Nnennaya
Chervova, Olga
Lucas, Olivia
Al-Sawaf, Othman
Hobson, Philip
Pawlik, Piotr
Stone, Richard Kevin
Hynds, Robert E.
Vendramin, Roberto
Saghafinia, Sadegh
López, Saioa
Gamble, Samuel
Ung, Seng Kuong Anakin
Vanloo, Sharon
Boeing, Stefan
Beck, Stephan
Bola, Supreet Kaur
Denner, Tamara
Mourikis, Thanos P.
Spanswick, Victoria
Barbè, Vittorio
Lu, Wei-Ting
Hill, William
Wu, Yin
Naito, Yutaka
Ramsden, Zoe
Veiga, Catarina
Royle, Gary
Collins-Fekete, Charles-Antoine
Fraioli, Francesco
Ashford, Paul
Clark, Tristan
Borg, Elaine
Wilson, James
Procter, Alexander James
Ahmed, Asia
Taylor, Magali N.
Nair, Arjun
Patrini, Davide
Martinoni Hoogenboom, Emilie
Monk, Fleur
Holding, James W.
Choudhary, Junaid
Bhakhri, Kunal
Scarci, Marco
Hayward, Martin
Panagiotopoulos, Nikolaos
Gorman, Pat
Khiroya, Reena
Stephens, Robert CM.
Wong, Yien Ning Sophia
Bandula, Steve
Sharp, Abigail
Smith, Sean
Gower, Nicole
Dhanda, Harjot Kaur
Chan, Kitty
Pilotti, Camilla
Leslie, Rachel
Grapa, Anca
Zhang, Hanyun
AbdulJabbar, Khalid
Pan, Xiaoxi
Yuan, Yinyin
Chuter, David
MacKenzie, Mairead
Chee, Serena
Alzetani, Aiman
Scarlett, Lydia
Richards, Jennifer
Ingram, Papawadee
Austin, Silvia
De Sousa, Paulo
Jordan, Simon
Rice, Alexandra
Raubenheimer, Hilgardt
Bhayani, Harshil
Ambrose, Lyn
Devaraj, Anand
Chavan, Hema
Begum, Sofina
Buderi, Silviu I.
Kaniu, Daniel
Malima, Mpho
Booth, Sarah
Fernandes, Nadia
Shah, Pratibha
Proli, Chiara
Danson, Sarah
Robinson, Lily
Dick, Craig
Kirk, Alan
Asif, Mo
Bilancia, Rocco
Kostoulas, Nikos
Thomas, Mathew
Jamal-Hanjani, Mariam http://orcid.org/0000-0003-1212-1259
McGranahan, Nicholas http://orcid.org/0000-0001-9537-4045
Swanton, Charles http://orcid.org/0000-0002-4299-3018
,
Article History
Received: 21 October 2021
Accepted: 2 February 2023
First Online: 12 April 2023
Competing interests
: A.M.F. is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). M.A.B. has consulted for Achilles Therapeutics. D.A.M. reports speaker fees from AstraZeneca, Eli Lilly and Takeda, consultancy fees from AstraZeneca, Thermo Fisher, Takeda, Amgen, Janssen, MIM Software, Bristol-Myers Squibb (BMS) and Eli Lilly and has received educational support from Takeda and Amgen. S.V. is a co-inventor on a patent to detect molecules in a sample (US patent 10578620). G.A.W. is employed by and has stock options in Achilles Therapeutics. R.S. reports non-financial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. C.A. has received speaking honoraria or expenses from Novartis, Roche, AstraZeneca and BMS and reports employment at AstraZeneca. C.A. is an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); the patent has been licensed to commercial entities and under their terms of employment, C.A. is due a revenue share of any revenue generated from such licence(s). C.A. declares a patent application (PCT/US2017/028013) for methods to detect lung cancer. C.A. is a named inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.A. is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. D.B. reports personal fees from NanoString and AstraZeneca. He has a patent (PCT/GB2020/050221) issued on methods for cancer prognostication. R.R. is an employee of and has stock options in Achilles Therapeutics and holds a European patent on targeting neoantigens (PCT/EP2016/059401) and in determining HLA LOH (PCT/GB2018/052004). D.A.F. reports grants from Aldeyra, Boehringer Ingelheim, Astex Therapeutics, Bayer, BMS, GSK, RS Oncology, Clovis, Eli Lilly, MSD, GSK, personal fees from Atara, BMS, Boehringer Ingelheim, Cambridge Clinical Laboratories, Targovax, Roche and RS Oncology. M.D.F. acknowledges grant support from CRUK, AstraZeneca, Boehringer Ingelheim, MSD and Merck; is an advisory board member for Transgene; and has consulted for Achilles, Amgen, AstraZeneca, Bayer, Boxer, BMS, Celgene, EQRx, Guardant Health, Immutep, Ixogen, Janssen, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pharmamar, Pfizer, Roche, Takeda and UltraHuman. K.S.P. is a co-founder of Achilles Therapeutics. S.A.Q. is a co-founder, stockholder and Chief Scientific Officer of Achilles Therapeutics. E.L. has received funding from AstraZeneca, Boehringer Ingelheim, Medela, Johnson & Johnson/Ethicon, Covidien/Medtronic, Guardant Health, Takeda, Lilly Oncology, Boehringer Ingelheim and Bayer. E.L. has received consulting fees from Beigene, Roche and BMS, honoraria from Medela and is a founder My Cancer Companion, Healthcare Companion Ltd. N.N. reports honoraria for non-promotional educational talks, advisory boards or conference attendance from Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, OncLive, PeerVoice, Pfizer and Takeda. S.M.J. has received fees for advisory board membership in the past 3 years from AstraZeneca, Bard1 Lifescience and Johnson & Johnson. He has received a grant income from Owlstone and GRAIL Inc. He has received assistance with travel to an academic meeting from Cheisi. C.D. has received research funding and educational research grants from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific and Neomed Therapeutics. C.D. has also received honoraria for consultancy and/or advisory boards from Biocartis, Merck, AstraZeneca, GRAIL and Boehringer Ingelheim. J.C. reports funding from Amgen to attend a conference. A. Hackshaw has received fees for being a member of Independent Data Monitoring Committees for Roche-sponsored clinical trials, and academic projects co-ordinated by Roche. N.J.B. is a co-inventor on a patent to identify responders to cancer treatment (PCT/GB2018/051912), has a patent application (PCT/GB2020/050221) on methods for cancer prognostication and is a co-inventor on a patent for methods for predicting anticancer responses (US14/466,208). C.T.H. has received speaker fees from AstraZeneca. M.J.-H. has consulted for and is a member of the Achilles Therapeutics Scientific Advisory Board (SAB) and Steering Committee, has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, and holds a patent (PCT/US2017/028013) relating to methods for lung cancer detection. This patent has been licensed to commercial entities and under terms of employment, M.J.-H. is due a share of any revenue generated from such licence(s). N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, BMS, Pfizer, Roche-Ventana, Invitae (previously Archer Dx (collaboration in minimal residual disease sequencing technologies)) and Ono Pharmaceutical. C.S. is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s SAB. He receives consultant fees from Achilles Therapeutics (also a SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre–Shanghai, Metabomed (until July 2022), and the Sarah Cannon Research Institute. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. is an inventor on a European patent application relating to an assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and under his terms of employment, C.S. is due a revenue share of any revenue generated from such licence(s). C.S. holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient responses to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying indel mutation targets (PCT/GB2018/051892) and is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.S. is a named inventor on a provisional patent related to a ctDNA detection algorithm.